Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
เนื้อหาจัดทำโดย Proactive Investors เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก Proactive Investors หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
Player FM - แอป Podcast
ออฟไลน์ด้วยแอป Player FM !
ออฟไลน์ด้วยแอป Player FM !
Healthcare outlook 2025: healthcare and biotech to regain investor focus
Manage episode 461207170 series 2891889
เนื้อหาจัดทำโดย Proactive Investors เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก Proactive Investors หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
The healthcare and biotech sectors are set to regain investor interest in 2024 due to long-term growth prospects, aided by structural drivers such as ageing populations and rising healthcare expenditure. Healthcare now contributes 10.2% of global GDP, with annual spending expected to reach $14 trillion by 2030. Previously overshadowed by technology, healthcare is now viewed as undervalued following small-cap underperformance last year. Anteris Technologies Global Corp (ASX:AVR, OTC:AMEUF) is advancing its DurAVR® Transcatheter Heart Valve to treat severe aortic stenosis, supported by an $88.8 million Nasdaq IPO to fund further development and clinical trials. Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is focused on synthetic anti-infectives targeting antibiotic-resistant bacteria and viral infections. Its flagship candidate, RECCE® 327, has received approval for a Phase 3 trial in Indonesia for diabetic foot infections, opening commercial avenues in the ASEAN region. Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) develops psilocin-based treatments for neuropsychiatric disorders. Interim results from a Phase 2A trial show potential for addressing Irritable Bowel Syndrome. Orthocell Ltd (ASX:OCC, OTC:ORHHF) targets regenerative medicine, with approved products such as Remplir™ for nerve repair and Striate Plus™ for dental applications. The company aims to expand into the US and other global markets. Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) specialises in rapid diagnostic tests. Its products, FebriDx® and ViraDx™, have received FDA approval, with ongoing efforts to expand within women’s health diagnostics. #HealthcareSector #Biotech #MedicalDevices #DrugDevelopment #RegenerativeMedicine #Diagnostics #BiotechInvesting #GlobalGDP #AorticStenosis #AntibioticResistance #Superbugs #PsilocybinResearch #ChronicPain #NerveRepair #DentalRegeneration #RapidDiagnostics #COVIDTesting #FluTesting #HealthcareInnovation #InvestorOutlook
…
continue reading
617 ตอน
Manage episode 461207170 series 2891889
เนื้อหาจัดทำโดย Proactive Investors เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก Proactive Investors หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
The healthcare and biotech sectors are set to regain investor interest in 2024 due to long-term growth prospects, aided by structural drivers such as ageing populations and rising healthcare expenditure. Healthcare now contributes 10.2% of global GDP, with annual spending expected to reach $14 trillion by 2030. Previously overshadowed by technology, healthcare is now viewed as undervalued following small-cap underperformance last year. Anteris Technologies Global Corp (ASX:AVR, OTC:AMEUF) is advancing its DurAVR® Transcatheter Heart Valve to treat severe aortic stenosis, supported by an $88.8 million Nasdaq IPO to fund further development and clinical trials. Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is focused on synthetic anti-infectives targeting antibiotic-resistant bacteria and viral infections. Its flagship candidate, RECCE® 327, has received approval for a Phase 3 trial in Indonesia for diabetic foot infections, opening commercial avenues in the ASEAN region. Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) develops psilocin-based treatments for neuropsychiatric disorders. Interim results from a Phase 2A trial show potential for addressing Irritable Bowel Syndrome. Orthocell Ltd (ASX:OCC, OTC:ORHHF) targets regenerative medicine, with approved products such as Remplir™ for nerve repair and Striate Plus™ for dental applications. The company aims to expand into the US and other global markets. Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) specialises in rapid diagnostic tests. Its products, FebriDx® and ViraDx™, have received FDA approval, with ongoing efforts to expand within women’s health diagnostics. #HealthcareSector #Biotech #MedicalDevices #DrugDevelopment #RegenerativeMedicine #Diagnostics #BiotechInvesting #GlobalGDP #AorticStenosis #AntibioticResistance #Superbugs #PsilocybinResearch #ChronicPain #NerveRepair #DentalRegeneration #RapidDiagnostics #COVIDTesting #FluTesting #HealthcareInnovation #InvestorOutlook
…
continue reading
617 ตอน
All episodes
×ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ